What You Missed at 3rd Raw Materials for Cell & Gene Therapy Summit
Move on from theory and step inside the conversations shaping how raw material strategies are implemented in practice. Across technical case studies, peer-led discussions, and interactive workshops, attendees explored how teams are managing suppliers, qualifying materials, overseeing supply chains, and navigating regulatory uncertainty in real-world settings.
Designed to encourage open dialogue, this meeting created space for candid, experience-driven exchange that dives in deep to create a one-stop-shop for everything they needed to know about raw materials and everyone that they needed to meet.
Attendees enjoyed a highly collaborative environment where they challenged assumptions, validated their approach, and left better equipped to make confident raw material decisions for their programs.
There Was Something for Everyone at the 3rd Raw Materials for Cell & Gene Therapy Summit
Shape Your End-to-End Raw Materials Strategy
Step back and assess the bigger picture with strategic sessions from Aspen Neuroscience, Genentech, and Fate Therapeutics, exploring how to build phase-appropriate raw material frameworks that support both development agility and long-term scale.
Technical Case Studies Across Modalities & Development Stages
Compare how Ray Therapeutics (AAV gene therapy), Cabaletta Bio (autologous cell therapy), and Tr1X Bio (allogeneic cell therapy) are tackling material qualification, variability, and purification challenges, and understand how strategies need to evolve from early development to commercial readiness.
Strengthen Supplier Engagement & Supply Chain Resilience
Hear from Bristol Myers Squibb and Kite Pharma on how to engage suppliers more strategically, qualify secondary sources, and protect continuity as programs move toward late-stage and commercial manufacturing.
Gain Clarity on Evolving Regulatory Expectations
Engage directly with the United States Pharmacopeia (USP) to understand how emerging standards and guidance are shaping raw material quality, risk assessment, and regulatory confidence for cell and gene therapies.
Explore the 2026 Full Event Guide
- 16+ cross-functional experts spanning quality, MSAT, and supply chain shaping raw material strategies
- 2 in-depth workshops to deep dive into particulate risk and material transitions before they delay your programme
- Dedicated networking sessions & interactive roundtables designed to spark meaningful, problem-solving conversations
- Face-to-face access to peers and decision-makers to exchange practical experiences not captured in published reports
Attending Companies Included
Explore the 2026 Agenda
Dive into technical case studies and working sessions designed to help you manage raw material risk, variability, and scale-up challenges with confidence.
Partner With Us
Position your solutions in front of cell and gene therapy leaders actively seeking support to strengthen material quality, reduce supply chain risks, and ensure overall manufacturing reliability.
Join Industry Leaders in 2027
Connect face-to-face with cross-functional experts to exchange candid insights and build relationships that accelerate your raw material strategy in practice.